Biointron's Q3 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September.
Antibody-oligonucleotide conjugates, or AOCs, are an emerging therapeutic format designed to combine two established biological tools: the targeting ability of antibodies and the gene-regulating activity of oligonucleotides.
On September 18, 2026, the FDA approved Isembyld (apitegromab-mstn) from Scholar Rock for spinal muscular atrophy (SMA), making it the first approved SMA therapy that directly targets muscle loss and the first approved antibody targeting the myostatin pathway for this indication. The drug is approved for adults and children aged 2 years and older who are already receiving an SMN2-targeted therapy.
Time: February 26, 2024
Location: San Diego, CA
Time: May 13-17, 2024
Location: Boston, MA
Booth: #613
Time: March 13 - 15, 2024
Location: London, UK
Booth: #31
AI is transforming antibody discovery, but better models only come from better data. When you are generating and screening sequences at scale, you need characterization results that are fast, comprehensive, and ready to use without hours of cleanup and reformatting.
The antibody therapeutics sector is rapidly evolving, transitioning from traditional hybridoma methods to single B and AI-driven de novo design approaches, significantly compressing discovery timelines and creating novel binding moieties.
Biointron’s 2026 Lunch & Learn, held at CIC Cambridge on May 8, 2026, featured expert presentations from SeromYx Systems and Visterra on two critical areas of antibody and biologic development: Fc-effector function profiling and cell-based neutralizing antibody (NAB) assay design.
When you’re a small biotech with big ambitions, every week counts. For Macomics Limited, that meant finding a way to get high-quality antibodies quick···
The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms.
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express t···
Get 50% off or a free plate with Biointron's RushData launch offer. 1-day CHO expression, high-throughput antibody characterization. Offer ends 12/31/26.
Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.
Submit a quick Biointron testimonial and we’ll send you a $25 Amazon gift card. Simple, fast, and appreciated!
Spotlight on Antibodies: we'll highlight how experimental data supports AI-guided antibody discovery, how antibody-oligonucleotide conjugates deliver gene-regulating therapies, and how messenger RNA can enable antibody production inside the body.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in August, we'll talk about engineering peptides into antibodies, the ADC therapeutic window, and targeting autoimmune memory.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month from July, we'll highlight antibodies for IVD applications, the druggable proteome, and degrader-antibody conjugates.
Recap of Antibodies After Hours Boston 2026: IPI's DELPHI developability prediction, CDR H3 polyreactivity insights, and Biointron's RushDATA™ wet-lab platform.
Key trends from the 17th World Bispecific Summit 2026 in Boston: AI-guided design, CD2/CD28 T-cell engagers, conditional antibodies, multispecific ADCs.
Biointron’s Antibodies After Hours: From Algorithms to Antibodies was held at The Hangar in South San Francisco, on Friday, September 4, 2026. “Antibodies After Hours” is a networking reception series from Biointron held in biotech hubs across the United States, with events previously hosted in S
You can also contact us on the Scientist and Science Exchange marketplaces.